Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  tamoxifen citrate
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 59
Trial IDs: CLEE011E2301, NCI-2014-02508, NCT02278120
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IFHCC 09-002, NCI-2014-01429, NCT01023477
Tamoxifen Citrate in Treating Patients with Stage III or IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E3108, NCI-2011-02067, CDR0000672523, ECOG-E3108, NCT01124695
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 and over
Trial IDs: 08218, NCI-2010-01976, 115422, NCT01196936
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GOG-3007, NCI-2015-00993, CRAD001CUS236T, NCT02228681
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients with Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A011203, NCI-2014-02409, NCT02311933
Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0508, NCI-2015-00508, NCT02366130
Pembrolizumab, Tamoxifen Citrate, and Vorinostat in Treating Patients with Hormone Receptor Positive Stage IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC #147523, NCI-2015-00815, 132069, 14-15383, 147523, NCT02395627
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15252, NCI-2014-01032, I3Y-MC-JPBH, NCT02057133
Mammaglobin-A DNA Vaccine in Treating Patients with Newly Diagnosed Breast Cancer Undergoing Endocrine Therapy before Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201407100, NCI-2014-01457, 14-x092, NCT02204098
Tamoxifen Citrate in Treating Patients with Barrett’s Esophagus
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 201404013, NCI-2014-00845, 14-x030, NCT02089386
Start Over